Restructuring |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Restructuring and Related Activities [Abstract] | |
| Restructuring | Note 4. Restructuring During both 2023 and 2024 the Company took multiple steps to reduce its headcount to curtail expenses and focus on its clinical development efforts, collectively referred to as its Clinical Reprioritization. As an on-going part of the Clinical Reprioritization, on April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $1,522, to be paid in two equal installments and (ii) the issuance of 66 RSUs which fully vest on the one-year anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment was paid on September 30, 2025. Each such installment payment was subject to the applicable employee’s continued employment through December 31, 2025. On September 16, 2025, the Company dissolved its operations in the Czech Republic and paid $194 in closure related expenses during the third quarter of 2025. |